Supervisory Board of Lek appoints new members of Lek's Board of Management
- Effective July 4, Lek's Board of Management will change for the period until September 1, 2024.
The Supervisory Board of Lek approved the changes to the membership of the company's Board of Management at its meeting at the end of June, following a proposal by Robert Ljoljo, President of the Board of Management of Lek d.d. and Sandoz Country President Slovenia. The changes in the Board of Management are related to the planned demerger of Lek, a Sandoz company, from Novartis.
From July 4, Lek's Board of Management will be composed of: Robert Ljoljo, President of the Board of Management of Lek, Andreja Bucik Primožič, Head of Finance, Eva Podgoršek, Head of Legal Affairs, Paulina Pazio, Head of P&O, Matjaž Tršek, Head of Sandoz Development Center Slovenia, Simon Rečnik, Head of Lendava Solids, Gregor Makuc, Head of Corporate Affairs and Marjan Novak, Workers' Director. The term of office of the current members of the Board of Management, Uroš Urleb, Raul Intriago Lombeida and Ksenija Butenko Černe, will expire on July 3.
Robert Ljoljo, who has been heading the company since September 2019, will remain President of the new Board and will be responsible for Strategic Programs and Commercial Operations (additional information).
Andreja Bucik Primožič is a member of the Board of Management in charge of Finance and Technology (additional information).
Eva Podgoršek is a member of the Board of Management in charge of for Legal Affairs and Compliance (additional information).
Paulina Pazio is a member of the Board of Management in charge of People & Organizations (additional information).
Matjaž Tršek is a member of the Board of Management in charge of Development (additional information).
Simon Rečnik is a member of the Board of Management in charge of Technical Operations (additional information).
Gregor Makuc is a member of the Board of Management in charge of Corporate Affairs (additional information).
Marjan Novak is the Workers' Director and a member of the Board of Management of Lek (additional information).
The term of office of all members of the Board of Management runs until September 1, 2024.
Lek, a Sandoz company, is the first and longest-standing pharmaceutical company in Slovenia, developing, manufacturing and marketing effective, safe and high-quality generics and biosimilars for patients around the world. Our work is guided by high ethical standards, innovative thinking and breakthrough achievements by our world-class experts. For decades, we have been actively shaping the Slovenian, European and global R&D landscape. With nearly 3000 associates, we are building a culture of open dialogue in Slovenia and proudly and responsibly hold the title of Slovenia's most reputable employer.
About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.
This press release contains statements and forecasts of future business operations. The forecasts include estimates based on all the information currently available to us. Should these forecasts prove unreliable, the actual results of business operations could be different from those expected.
Forfurther information, please contact:
Gregor Makuc
Corporate Affairs
Lek Pharmaceuticals d.d.
Telephone: 01 580 22 43
gregor.makuc@sandoz.com
